Iantrek Raises $23M Series B Financing To Advance Next Generation Ophthalmic Micro-Interventional Technologies

Aug 30, 2022•over 3 years ago

Amount Raised

$23 Million

Round Type

series b

White PlainsBiotechnology

Description

Iantrek, Inc., a medical device company founded by ophthalmic innovator Dr. Sean Ianchulev, announced the closing of a $23M Series B financing. The oversubscribed financing was led by institutional investors Visionary Ventures and Sectoral Asset Management, Inc. The capital will be used to initiate clinical introduction and post-marketing studies of Iantrek’s Micro-Interventional Glaucoma Surgical (MIGS) devices in the United States

Company Information

Company

Iantrek

Location

151 EAST POST ROAD

White Plains, New York, United States

About

Iantrek, Inc. is a medical technology company founded by ophthalmic innovator Dr. Tsontcho Ianchulev, which is focused on micro- and bio-interventional solutions to advance the surgical treatment of chronic eye diseases. The company has developed a comprehensive late-stage portfolio for ophthalmic interventions and is advancing next-generation micro-surgical instrumentation and biologic tissue solutions for surgeons and patients.

Related People

2 contacts

Funding Insights

Based on industry data

Tech investment trends

83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech

Iantrek Raises $23M Series B Financing To Advance Next Generation Ophthalmic Micro-Interventional Technologies

Description

.css-1v6jzuu{--tw-text-opacity:1;color:rgba(75, 85, 99, var(--tw-text-opacity));}Company Information

Related People

Funding Insights

Company Information